Piper Jaffray Downgrades Orexigen Therapeutics (OREX) to Neutral

RBC Capital Sees Tough Road Ahead Following Orexigen Therapeutics' (OREX) Takeda Partnership Termination; Cuts PT to $0.60

RBC Capital maintained a Sector Perform rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $0.60 (from $1.00), following the company's announced termination of the Takeda partnership. OREX plans to commercialize Contrave in the US by building its own commercial infrastructure. As... More

Leerink Lowers Leerink (OREX) PT to $1 on Move to Acquire Contrave Rights from Takeda

Leerink Partners analyst, Paul Matteis, noted that Orexigen Therapeutics (NASDAQ: OREX) acquired the Contrave rights from Takeda and lowered his price target to $1 (from $2) on shares as a result. The firm maintained its Market Perform rating.

Yesterday morning OREX announced that it has entered into a deal with Takeda where it will acquire US commercial rights to Contrave; concurrently, OREX also... More

Orexigen Therapeutics (OREX) Files $150M Mixed Shelf

Orexigen Therapeutics (NASDAQ: OREX) filed a registration with the U.S. SEC to sell up to $150 million worth of mixed securities.

Orexigen Therapeutics (OREX) Enters Mysimba Commercialization Agreement with Valeant (VRX)

Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. The distribution agreement between Valeant Holdings Ireland and Orexigen's wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., includes 12 countries where Mysimba has been approved for marketing in the European Union (EU): Greece, Slovenia, Slovakia, Czech Republic, Hungary, Croatia, Lithuania, Estonia, Poland, Latvia, Bulgaria, and Romania. The agreement also extends to several non-EU countries where Valeant will apply for marketing authorization: Serbia, Bosnia and Herzegovina, Albania, Macedonia, Montenegro,... More

Orexigen (OREX), Takeda to Terminate CONTRAVE Amended, Restated Collaboration Agreement

Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, announced they have agreed to terminate the Amended and Restated Collaboration Agreement for CONTRAVE (naltrexone HCl / bupropion HCl), the market leading national branded prescription treatment option for certain overweight and obese adults for... More